Babraham Institute Enterprise (BIE) has welcomed four new Non-Executive Directors to its Board. The new Directors are: Dr.

The Institute is delighted to welcome four new Non-Executive Directors to the Board of Babraham Institute Enterprise (BIE) ...

I would just add, Laura, that usually we prefer not to sell or to offer the data as a standalone product but to offer it in the mid -- in like a mix of other services, mostly media. And it's hard ...

Correspondence to Dr Laura C Coates, Nuffield Department of Orthopaedics Rheumatology ... MGHvdS has received speakers/consultancy fees from Takeda, Tillotts and Benecke MSD. DB has received research ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

CESI held its conference discussing issues and solutions around housing and standard of living in Central Coast.

Cal Lutheran School of Management held a recruiting event in Vienna, Linz, and Graz for the EMBA in Austria program. Hub101 ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...